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Abstract
Atherosclerotic lesions that critically narrow the artery can necessitate an angioplasty and
stent implantation. Long-term therapeutic effects, however, are limited by excessive arterial
remodeling. We here employed a miniaturized nitinol-stent coated with star-shaped poly-
ethylenglycole (star-PEG), and evaluated its bio-functionalization with RGD and CXCL1 for
improving in-stent stenosis after implantation into carotid arteries of mice. Nitinol foils or
stents (bare metal) were coated with star-PEG, and bio-functionalized with RGD, or RGD/
CXCL1. Cell adhesion to star-PEG-coated nitinol foils was unaltered or reduced, whereas
bio-functionalization with RGD but foremost RGD/CXCL1 increased adhesion of early
angiogenic outgrowth cells (EOCs) and endothelial cells but not smooth muscle cells when
compared with bare metal foils. Stimulation of cells with RGD/CXCL1 furthermore increased
the proliferation of EOCs. In vivo, bio-functionalization with RGD/CXCL1 significantly
reduced neointima formation and thrombus formation, and increased re-endothelialization
in apoE-/- carotid arteries compared with bare-metal nitinol stents, star-PEG-coated stents,
and stents bio-functionalized with RGD only. Bio-functionalization of star-PEG-coated niti-
nol-stents with RGD/CXCL1 reduced in-stent neointima formation. By supporting the adhe-
sion and proliferation of endothelial progenitor cells, RGD/CXCL1 coating of stents may
help to accelerate endothelial repair after stent implantation, and thus may harbor the poten-
tial to limit the complication of in-stent restenosis in clinical approaches.
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Introduction
Cardiovascular disease is the most frequent cause of death in industrialized nations. Athero-
sclerosis as the underlying disease [1,2] can result in a narrowing of the artery, necessitating
angioplasty and stent-implantation. Long-term effects of such therapy, however, are limited by
arterial remodeling and restenosis, and the risk of life-threatening stent-thrombosis [3,4].
While meta-analyses have shown no differences in stent thrombosis comparing drug-eluting
with bare-metal stents [5–7], there is also evidence of an increased risk of very late stent throm-
bosis with drug-eluting stents [6,8–10], possibly related to reduced vessel wall re-endotheliali-
zation [11–13].
Different factors contribute to endothelial repair and plaque formation. The chemokine
CXCL1 enhances re-endothelialization and reduces neointima formation, and its receptor
CXCR2 mediates homing of circulating endothelial progenitor cells to sites of arterial injury in
mice [14–16]. Furthermore, stents coated with cRGD (Arg-Gly-Asp)-peptide, which preferen-
tially bind αvβ3 and α5β-integrins, attract endothelial progenitor cells to stented areas, acceler-
ating wound healing in swine [17].
Thus, RGD and CXCL1 may serve as candidates for the coating of stents to enhance re-
endothelialization after implantation. We here employed a miniaturized stent implanted into
the carotid artery of mice [18], and evaluated its bio-functionalization. Indeed, we could show
that the bio-functionalization of star-PEG-coated nitinol-stents with RGD/CXCL1 supported




Isolation and cell culture of early angiogenic outgrowth cells (EOCs) were performed as
described [14,19–22]. Briefly, peripheral blood mononuclear cells were separated by Biocoll
density gradient centrifugation (Biochrom) from buffy coats derived from healthy human
donors and plated on fibronectin-coated (10μg/ml) 6-well plates (1x107 cells/well) in endothe-
lial growth mediumMV2 (PromoCell), changed at day 1 and 4, and harvested at day 7. Under
these conditions, cultured cells developed a spindle-shaped appearance, formed typical cell
clusters and bound endothelial-specific lectin, identifying these as early angiogenic outgrowth
cells. Human umbilical vein endothelial cells (HUVECs, PromoCell, Cat. No. C-12200) were
cultured in endothelial cell growth medium and used between passages 3 to 6. Human coro-
nary artery smooth muscle cells (SMCs, PromoCell, Cat. No. C-12511) were cultured in
smooth muscle cell growth medium 2 (PromoCell) and used between passages 3 to 6. Adherent
cells were detached for experiments by applying accutase (PAA Laboratories) for 5 minutes at
37°C.
Stent braiding- and nitinol-coating
Stents or nitinol foils were processed as previously described [18]. Stents were manually
braided using 16 nitinol wires (50μm diameter) yielding an outer dimension of 500μm, and
heated in a high-temperature oven for shape settings. Stents or nitinol foils were cleaned by
sonication in acetone, water, and 2-propanol followed by drying in a nitrogen stream. Surface
activation was achieved by treatment with UV/ozone before use for aminofunctionalization.
Substrates were immersed in a solution of N-[3-(trimethoxysilyl)-propyl]ethylenediamine in
dry toluene, and the desired amount of isocyanate end group terminated six-arm star-shaped
copolymer of 80% ethylene oxide and 20% propylene oxide NCO-sP(EO-stat-PO)
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(Mn = 12,000g/mol; PD = 1.15) was dissolved in dry tetrahydrofurane under an inert gas atmo-
sphere. Thereafter, the solution was filtered through 0.2 μm syringe filters and used for hydro-
gel coating (5 min) of stents or foils. Subsequently, biofunctionalization was achieved by
overnight incubation in 300μl polymer solution containing 50μg/ml RGD or 50μg/ml RGD
and 1μg/ml CXCL1 in PBS, followed by extensive washing in water.
Adhesion assay under static conditions
For adhesion assays under static conditions, 1x105 cells were seeded on nitinol foils coated with
star-PEG with/without RGD and/or CXCL1. After an overnight incubation and 2 washing
steps with 1x Dulbecco’s PBS (PAA), adherent cells were detected by staining with DAPI and
visualized with a Leica DM-RXE fluorescence microscope. Adherent cells were quantified in 15
recorded high power fields per sample using Diskus software.
Proliferation and viability assay
Proliferation assays were performed in untreated cells, or after stimulation with RGD or a com-
bination of RGD together with CXCL1 using the BrdU Cell Proliferation Assay, HTS (Calbio-
chem), according to the manufacturers’ instructions using 1x105 cells/well in 96-well plates.
Viability was tested using the fluorescent CellTiter-Blue1 cell viability assay (Promega),
according to the manufacturers’ instructions.
Stent implantation and Immunohistochemistry
Stents were implanted into left carotid arteries of anesthetized (100 mg/kg ketamine hydro-
chloride and 10 mg/kg xylazine intraperitoneally) mice by inserting 500 μm silicon tubes con-
taining the stent through an incision in the external carotid artery, and careful forward-feeding
of the stent whilst retraction of the tube allowing for shape memory-based expansion [18]. In
total, 38 mice underwent stent implantation but 6 mice died during the procedure and there-
fore were not considered for further analyses. All other 32 mice showed normal physiological
behavior after the procedure and did not require any special treatment during the experiment.
The following treatment groups were analyzed: n = 4 apolipoprotein E-deficient (apoE-/-) mice
were implanted with bare metal nitinol-stents, n = 5 apoE-/- mice were implanted with nitinol-
stents coated with star-PEG, n = 9 apoE-/- mice were implanted with star-PEG-coated stents
bio-functionalized with RGD and n = 8 apoE-/- mice were implanted with star-PEG-coated
stents bio-functionalized with RGD/CXCL1. All apoE-/- mice were placed on a high-fat diet
containing 21% fat and 0.15% cholesterol (Altromin) after the procedure. C57Bl/6 control
mice (n = 6) were implanted with bare metal nitinol-stents and fed a normal chow-diet fed
(Ssniff). Mice were sacrificed one week after stent placement under anesthesia (100 mg/kg keta-
mine hydrochloride and 10 mg/kg xylazine intraperitoneally) by intracardiac puncture and
exsanguination, and the carotid arteries were fixed in situ with 4% paraformaldehyde. All
experiments were conducted in accordance with the guidelines for the care and use of labora-
tory animals and approved by the Landesamt für Natur, Umwelt- und Verbraucherschutz
Nordrhein-Westfalen (permit number 82–02.04.2011.A333) and complied with the German
animal protection law. All surgeries were performed under ketamine/xylazin anesthesia and all
efforts were made to minimize suffering. Carotid arteries were subsequently embedded in
Technovit 9100NEU (Heraeus Kulzer). Serial sections (50μm; 3–5 per mouse) were generated
within 500μm from the bifurcation using a cutting-grinding system technique (Exakt 400CS)
with a diamond-band saw (Exakt 300) and quantified by Giemsa staining and planimetry of
the area within elastic laminae and of the lumen (Diskus software, Hilgers); organized thrombi
were detectable by black staining of fibrin depositions inside the neointima. Re-
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endothelialization of luminal surface was detected after deplasting sections with xylene,
2-methoxyethylacrylate (MEA) and acetone and staining for endothelial cells using vWF mAb
(clone A0082, DAKO) and secondary Cy3-conjugated Ab (Sigma Aldrich). Isotype controls
(appropriate IgGs) and right carotid arteries served as controls. Images were recorded using a
Leica DM-RXE fluorescence microscope and quantified with Diskus software.
Statistical analysis
Data are expressed as mean±SEM. Statistical calculations were performed using GraphPad
Prism 6 (GraphPad Software Inc.). Data were tested for normality (D'Agostino and Pearson
omnibus normality test) prior to analysis and non-parametric statistics as applicable. One-way
ANOVA analysis followed by the Tukey’s multiple comparison test or, if non-parametric,
Kruskal-Wallis test followed by the Dunn’s post-test were applied as appropriate and indicated.
P-values<0.05 were considered statistically significant.
Results
The effects of RGD and CXCL1 on cell adhesion were evaluated when employed as specific sur-
face coatings in vitro. EOCs, HUVECs and SMCs were seeded on bare metal nitinol-foils with/
without coating with star-PEG, bio-functionalized with RGD, or RGD in combination with
CXCL1. A significant increase in EOC and HUVEC adhesion to RGD but foremost RGD/
CXCL1-biofunctionalized foils was revealed compared to bare-metal controls or star-PEG-coated
foils (Fig 1A). In contrast, SMC adhesion was not altered by RGD/CXCL1 bio-functionalization,
Fig 1. Biofunctionalization with RGD/CXCL1 triggers endothelial cell adhesion. (a) Cells were seeded onto nitinol-foils (control), and nitinol-foils coated
with star-PEG, or star-PEG-coated foils bio-functionalized with RGD or RGD/CXCL1. Adherent cells were quantified after 12 hours (n = 10–12). *P<0.05 vs.
controls, #P<0.05 vs. star-PEG, and §P<0.05 vs. star-PEG+RGD-coated foils. One-way-ANOVA with Tukey’s multiple comparison test. (b) Cell proliferation
was assessed by BrdU-incorporation (n = 9 each) after indicated stimulation, expressed relative to untreated cells (control). *P<0.05 vs. controls and #P<0.05
vs. RGD. One-way-ANOVA with Tukey’s multiple comparison test.
doi:10.1371/journal.pone.0155829.g001
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and even blocked by star-PEG coating alone (Fig 1A). Stimulation of cells with RGD/CXCL1 sig-
nificantly augmented the proliferation of EOCs but not HUVECs, whereas proliferation of SMCs
was even inhibited compared to untreated cells (Fig 1B). None of these treatments impaired cell
viability of HUVECs and SMCs (Fig 2). These data indicate that the combination of RGD/
CXCL1 provides support for EOC adhesion and proliferation, and the attachment of HUVECs
and SMCs, but not their proliferation.
To scrutinize effects of these coatings in vivo, in-stent intima formation was assessed in
carotid arteries of apoE-/-mice one week after stent placement as a model of in-stent stenosis in
hyperlipidemic subjects. In contrast to drug-eluting stents for human application, where the
kinetics of drug-delivery are of crucial importance, stents used in our study were coated with a
polymer, to which RGD and/or CXCL1 were covalently linked, ensuring a densely packed poly-
mer network to produce a RGD and/or CXCL1-coated surface, which keeps its nonfouling prop-
erties for at least 7 days [23] and up to 4 weeks at 37°C [24]. We confirmed the stability of the
stent coatings after 7-days of washing in PBS under agitation at 37°C by incubation with RITC-
conjugated BSA, and could detect an overall unspecific protein binding on only aminofunctiona-
lized stents, whereas no signal could be detected on star-PEG coated stents (data no shown).
Compared to C57Bl/6 mice on normal chow diet, the significant increase in in-stent steno-
sis, evidenced in high-fat diet fed apoE-/-mice implanted with bare-metal nitinol-stents, star-
PEG-coated stents, or stents bio-functionalized with RGD, could be reduced by bio-functionaliza-
tion with RGD/CXCL1 (Fig 3A and 3B). Thrombus formation was increased in arteries implanted
with star-PEG-coated stents, but reduced in RGD-bio-functionalized stents, and almost
completely prevented by bio-functionalization with RGD/CXCL1 (Fig 3C). Conversely, re-
endothelialization was significantly increased in RGD/CXCL1-bio-functionalized stents (Fig 3D).
These data indicate that bio-functionalizing of star-PEG-coated nitinol-stents with RGD/
CXCL1 reduces intima formation after implantation in apoE-/- mice, associated with an
enhanced re-endothelialization.
Discussion
Revascularizing interventions and stent-implantation lead to a mechanic injury of the endothe-
lial cell lining, inducing thrombocyte aggregation at the injured artery. The administration of
thrombocyte aggregation inhibitors is therefore mandatory, but associated with severe bleeding
complications [3]. SMC proliferation predominates neointimal hyperplasia at later stages, and
is targeted by the drug-eluting stents that inhibit cell proliferation. These therapies, however,
Fig 2. Treatment of HUVECs and SMCs with RGD and CXCL-1 does not impair cell viability. In vitro viability assay of HUVECs and SMCs after
stimulation with RGD, CXCL-1 or RGD and CXCL-1 together for 4, 24 and 48h. *P<0.05 (shown is significant difference compared to control). Two-
way-ANOVAwith Bonferroni post-test.
doi:10.1371/journal.pone.0155829.g002
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can also impair endothelial cell recovery [12], which can precipitate life-threatening late stent-
thrombosis. Treatment approaches are therefore required to selectively enhance endothelial
recovery after stent-implantation.
We here defined the use of stents coated with a combination of signaling molecules for spe-
cifically attracting cells for endothelial repair. We demonstrate that star-PEG bio-functionali-
zation with RGD/CXCL1 effectively supports the adhesion and proliferation of EOCs, and
allows the attachment of HUVECs and SMCs, but not their proliferation.
These properties may help to selectively recruit and propagate endothelial cells to cover the
stent surface. This notion is supported by in vivo evidence showing an accelerated re-endothe-
lialization of RGD/CXCL1-coated stents in carotid arteries of apoE-/- mice. In consequence,
this may also protect from thrombus formation and enhanced intima formation.
Taken together, our findings indicate that in-stent neointima formation can be reduced by
bio-functionalizing star-PEG-coated stents with RGD and CXCL1, harboring the potential of
limiting in-stent restenosis in clinical approaches.
Fig 3. RGD/CXCL1-biofunctionalized stents reduce neointima formation. (a-d) Carotid arteries of C57Bl/6 (n = 6) or apoE-/- mice were analyzed
one week after implantation of bare metal nitinol-stents (BM, n = 4), star-PEG-coated nitinol-stents (n = 5) or star-PEG-coated stents bio-functionalized
with RGD (n = 9) or RGD/CXCL1 (n = 8). (a) Representative Giemsa-stained sections (scale bars, 200μm) from apoE-/- mice. Quantification of in-stent
intima formation (b) and thrombus formation (c). (d) Representative images of vWF-staining (red); cell nuclei were counterstained by DAPI (L, lumen; x,
stent struts; scale bar, 50μm); quantification of re-endothelialization. *P<0.05. Kruskal-Wallis test with Dunn’s post-test.
doi:10.1371/journal.pone.0155829.g003
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